Bladder cancer is a complex disease that poses high risks of morbidity and mortality, especially when not treated optimally. Hematuria is the most common presenting symptom in patients with bladder ...
In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...
MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC. MRI-based assessment may eliminate the need for transurethral resection of bladder tumor ...
Prostate cancer researchers Urine cytology after an initial TURBT predicted risk for a second TURBT one month later. The following article features coverage from the American Urological Association ...
OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...
Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
OSLO, Norway, Sept. 20, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of first results from the Laser III clinical study in the medical journal, European ...
After a diagnosis of urothelial cancer, doctors will assign a stage to the disease -- determining how deep the tumor has invaded into the bladder and whether there is any spread to the lymph nodes and ...
MILAN — Photodynamic diagnosis-guided transurethral resection of bladder tumors did not reduce recurrence rates of non–muscle-invasive bladder cancer (NMIBC) in the longer term compared with standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results